Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 23Vincristine 16Prednisone 16Methotrexate 15prednylidene 13deltacortene 13blinatumomab 13merphos 12Specimen Handling 12Cytarabine 12N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Doxorubicin 10Dexamethasone 10pegaspargase 9azathiopurine 9Etoposide 9Biopsy 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Spinal Puncture 8Rituximab 8Calcium Dobesilate 8venetoclax 7fludarabine 7Leucovorin 7Thioguanine 6Magnetic Resonance Spectroscopy 6Daunorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Leyk × 30 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡